UBE2T and head and neck squamous cell carcinoma: The drug M435-1279, an inhibitor of the ubiquitin-conjugating enzyme E2T (UBE2T) that catalyzes RACK1 degradation, is currently being studied for its efficacy in HNSCC (but is being investigated in GC for now) [214].